Efficacy News and Research

RSS
Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

International scientists identify novel genetic defects that induce oesophageal cancer

International scientists identify novel genetic defects that induce oesophageal cancer

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Study lays groundwork for PET imaging studies on human Menkes disease

Study lays groundwork for PET imaging studies on human Menkes disease

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

Scientists discover why cerebellar granule cell neurons in A-T patients fail to repair DNA damage

Scientists discover why cerebellar granule cell neurons in A-T patients fail to repair DNA damage

Study finds effectiveness of brief behavioral and mental health programs in pediatric practices

Study finds effectiveness of brief behavioral and mental health programs in pediatric practices

Axonics Modulation Technologies completes $32.6 million Series A preferred stock financing

Axonics Modulation Technologies completes $32.6 million Series A preferred stock financing

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.